Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) Overview 5 Therapeutics Development 6 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Stage of Development 6 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Therapy Area 7 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Indication 8 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Products Glance 9 Early Stage Products 9 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Companies 10 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Universities/Institutes 12 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Molecule Type 17 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Companies Involved in Therapeutics Development 18 Selvita S.A. 18 Takeda Pharmaceutical Company Limited 19 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Drug Profiles 20 BTZO-2 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 HYCO-1 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 SEL-303 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Small Molecule to Activate HO-1 for Endothelial Dysfunction, Asthma and Osteoarthritis - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Small Molecules to Activate HO-1 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Dormant Projects 25 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28

List of Tables Number of Products under Development for, H2 2016 6 Number of Products under Development by Therapy Area, H2 2016 7 Number of Products under Development by Indication, H2 2016 8 Comparative Analysis by Early Stage Products, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Products under Investigation by Universities/Institutes, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 17 Pipeline by Selvita S.A., H2 2016 18 Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 19 Dormant Projects, H2 2016 25 Dormant Projects (Contd..1), H2 2016 26 List of Figures Number of Products under Development for, H2 2016 6 Number of Products under Development by Therapy Area, H2 2016 7 Number of Products under Development by Indication, H2 2016 8 Comparative Analysis by Early Stage Products, H2 2016 9 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Mechanism of Actions, H2 2016 15 Number of Products by Stage and Mechanism of Actions, H2 2016 15 Number of Products by Stage and Molecule Type, H2 2016 17

Selvita S.A. Takeda Pharmaceutical Company Limited